CD47 Knock-out cell line

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: CD47 Knock-out cell line
• Cancer: Skin cancer
• Cancers detailed: Melanoma;Tumor microenvironment
• Research fields: Cancer;Cell signaling and signal transduction;Drug development
• Tool sub type: Continuous
• Parental cell: B16F10
• Organism: Mouse
• Tissue: Skin
• Disease: Cancer
• Model: Knock-Out
• Description: CRISPR/Cas9 edited B16F10 cell line designed to help uncover the impact of editing a cell surface protein (CD47), in a tumor microenvironment, and its use as a whole-cell vaccine. CRISPR edited B16F10 cells.
• Production details: Cells were cultured in high glucose DMEM and supplemented with 10% v/v Fetal Bovine Serum (FBS)
• Additional notes: CRISPR edited B16F10 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can pro...
• Recommended controls: B16F10 parental cells

Target Details

• Target: CD47

Applications

• Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

Handling

• Format: Frozen
• Unit size: 1x10^6 cells / vial
• Shipping conditions: Dry ice

References

• Inducing Tumor Suppressive Microenvironments through Genome Edited CD47 -/- Syngeneic Cell Vaccination